CENTURY THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.03 USD | +1.85% |
|
-23.91% | -10.39% |
| Apr. 12 | Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating | MT |
| Apr. 11 | Syncona agrees to sell stake in investee company for GBP7.4 million | AN |
Financials (USD)
| Sales 2024 * | 1.02M | Sales 2025 * | 22.93M | Capitalization | 193M |
|---|---|---|---|---|---|
| Net income 2024 * | -137M | Net income 2025 * | -138M | EV / Sales 2024 * | 189 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.41 x |
| P/E ratio 2024 * |
-1.45
x | P/E ratio 2025 * |
-1.58
x | Employees | 159 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.58% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +4.75% | ||
| 1 week | -26.54% | ||
| Current month | -28.83% | ||
| 1 month | -37.37% | ||
| 3 months | -22.93% | ||
| 6 months | +91.94% | ||
| Current year | -10.39% |
1 week
2.75
3.99
1 month
2.755.24
Current year
2.755.51
1 year
1.285.51
3 years
1.2832.90
5 years
1.2832.90
10 years
1.2832.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | Dec. 03 | |
Douglas Carr
DFI | Director of Finance/CFO | - | 18-09-30 |
Kenneth J. Dow
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Timothy Walbert
BRD | Director/Board Member | 57 | 22-09-30 |
Joseph Jimenez
CHM | Chairman | 64 | 19-07-31 |
Cynthia Butitta
BRD | Director/Board Member | 70 | 21-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +4.47% | - | |
| 0.00% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 2.975 | 0.00% | 31 160 |
| 24-04-18 | 2.975 | +4.75% | 145,448 |
| 24-04-17 | 2.84 | -9.55% | 179,248 |
| 24-04-16 | 3.14 | -14.44% | 320,558 |
| 24-04-15 | 3.67 | -6.14% | 42,136 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Companyâs product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.975
USD
Average target price
14.83
USD
Spread / Average Target
+398.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.39% | 193M | |
| -1.82% | 41.35B | |
| +42.21% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- IPSC Stock
